246 related articles for article (PubMed ID: 22822048)
21. Biomarkers of pituitary neoplasms: a review (Part II).
Salehi F; Agur A; Scheithauer BW; Kovacs K; Lloyd RV; Cusimano M
Neurosurgery; 2010 Dec; 67(6):1790-8; discussion 1798. PubMed ID: 21107210
[TBL] [Abstract][Full Text] [Related]
22. CD147 expression in pituitary adenomas and its significance for clinical outcome.
Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
[TBL] [Abstract][Full Text] [Related]
23. Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis.
Hui P; Xu X; Xu L; Hui G; Wu S; Lan Q
Int J Clin Exp Pathol; 2015; 8(4):3556-67. PubMed ID: 26097538
[TBL] [Abstract][Full Text] [Related]
24. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
25. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
26. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE; Simpson DJ; Bicknell JE; Talbot AJ; Bates AS; Clayton RN
Cancer Res; 1997 Jul; 57(13):2703-9. PubMed ID: 9205080
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs and Target Genes in Pituitary Adenomas.
Feng Y; Mao ZG; Wang X; Du Q; Jian M; Zhu D; Xiao Z; Wang HJ; Zhu YH
Horm Metab Res; 2018 Mar; 50(3):179-192. PubMed ID: 29351706
[TBL] [Abstract][Full Text] [Related]
28. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior.
Pegolo G; Buckwalter JG; Weiss MH; Hinton DR
Acta Cytol; 1995; 39(5):887-92. PubMed ID: 7571965
[TBL] [Abstract][Full Text] [Related]
29. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation.
Sperveslage J; Gierke M; Capper D; Honegger J; Sipos B; Beschorner R; Schittenhelm J
Acta Neuropathol; 2013 Jun; 125(6):911-2. PubMed ID: 23589031
[No Abstract] [Full Text] [Related]
30. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
31. Indices of apoptosis and proliferation as potential prognostic markers in non-functioning pituitary adenomas.
Ibrahim AE; Pickering RM; Gawne-Cain ML; King S; Lees PD; Ellison DW
Clin Neuropathol; 2004; 23(1):8-15. PubMed ID: 14986928
[TBL] [Abstract][Full Text] [Related]
32. Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.
Hou XZ; Liu W; Fan HT; Liu B; Pang B; Xin T; Xu SC; Pang Q
Neuro Oncol; 2010 Aug; 12(8):799-803. PubMed ID: 20200025
[TBL] [Abstract][Full Text] [Related]
33. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
Gejman R; Swearingen B; Hedley-Whyte ET
Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers of pituitary neoplasms.
Sav A; Rotondo F; Syro LV; Scheithauer BW; Kovacs K
Anticancer Res; 2012 Nov; 32(11):4639-54. PubMed ID: 23155226
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the MEN1 gene in sporadic pituitary adenomas.
Schmidt MC; Henke RT; Stangl AP; Meyer-Puttlitz B; Stoffel-Wagner B; Schramm J; von Deimling A
J Pathol; 1999 Jun; 188(2):168-73. PubMed ID: 10398160
[TBL] [Abstract][Full Text] [Related]
36. Aggressive pituitary adenomas--diagnosis and emerging treatments.
Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
[TBL] [Abstract][Full Text] [Related]
37. Pituitary adenoma: a DNA flow cytometric study of 192 clinicopathologically characterized tumors.
Gaffey TA; Scheithauer BW; Leech RW; Blick K; Kovacs K; Horvath E; Weaver AL; Lloyd RV; Ebersold M; Laws ER; DeBault LE
Clin Neuropathol; 2005; 24(2):56-63. PubMed ID: 15803804
[TBL] [Abstract][Full Text] [Related]
38. Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice.
Gordon J; Del Valle L; Otte J; Khalili K
Oncogene; 2000 Oct; 19(42):4840-6. PubMed ID: 11039901
[TBL] [Abstract][Full Text] [Related]
39. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
Nishioka H; Inoshita N
Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
[TBL] [Abstract][Full Text] [Related]
40. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.
Bottoni A; Zatelli MC; Ferracin M; Tagliati F; Piccin D; Vignali C; Calin GA; Negrini M; Croce CM; Degli Uberti EC
J Cell Physiol; 2007 Feb; 210(2):370-7. PubMed ID: 17111382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
